Spyre Therapeutics insider selling draws attention after Fairmount reports a $399.7 million Form 4 stock sale.
Insider Trading
June 24, 2026
Table of Contents
June 24, 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) disclosed that Fairmount Funds Management LLC, a director-linked reporting person, sold approximately $399.7 million worth of company shares, according to a Form 4 filing with the U.S. Securities and Exchange Commission (SEC).
The transaction occurred on June 23, 2026. The filing showed 4,684,781 shares sold at an average price of $85.31 per share.
After the reported sale, the filing listed zero shares remaining for the Fairmount Healthcare Fund II L.P. position tied to the transaction.
Spyre Therapeutics is a biotechnology company developing antibody-based therapies for immune-mediated diseases, including inflammatory bowel disease.
The sale is notable because it is far above typical insider and major-holder selling thresholds.
Single insider or director-linked sales above $1 million are generally worth reviewing, while sales above $5 million tend to draw greater attention.
In this case, the reported sale totaled nearly $400 million, making it a major ownership-related filing.
The Form 4 also showed a related acquisition of 666,680 shares through a conversion transaction before the reported sale.
That matters because the filing was not just a simple one-line open-market sale. It included a conversion or share-related transaction followed by the sale of 4,684,781 shares.
The key market transaction was the sale at $85.31 per share.
The filing listed zero shares remaining for the Fairmount Healthcare Fund II L.P. position after the sale.
That makes the transaction more notable than a partial liquidity event for that specific listed holding.
The filing also listed separate indirect ownership lines tied to other reporting persons, so the zero-share figure should be read as applying to the specific fund position shown in the transaction line.
Large fund sales can reflect portfolio management, liquidity planning, ownership restructuring, investment fund lifecycle decisions, or rebalancing rather than a direct operating signal from the company.
Still, the size of the sale and the reported reduction to zero for the listed fund position make the filing relevant for investors tracking insider and major-holder activity.
Major insider and holder sales become more meaningful when they exceed common dollar thresholds, involve director-linked entities, or reduce a reported ownership position sharply.
Platforms like LevelFields aggregate insider transactions and flag when activity exceeds key thresholds, helping investors identify when selling activity exceeds key thresholds and may signal a meaningful change in ownership behavior.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE